Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Zhao M, Scott S, Evans KW, Yuca E, et al. Clin Cancer Res 2021;27:1681-1694.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao M, Scott S, Evans KW, Yuca E, et al. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clin Cancer Res 2021;27:1681-1694.
PMID: 33414137